News

1 to 9 of 32 results

Modern Biosciences announces RA R&D agreement with Janssen Biotech

Modern Biosciences announces RA R&D agreement with Janssen Biotech

27-11-2014

UK-based drug development company Modern Biosciences has entered into an R&D alliance and global option…

Anti-Arthritics/RheumaticsBiotechnologyJanssen BiotechLicensingModern BiosciencesUK

Stada Arz and mAbxience to negotiate over adalimumab biosimilar

21-11-2014

German drugmaker Stada Arzneimittel and the biotech specialist mAbxience have agreed to negotiate over…

AbbVieadalimumabAnti-Arthritics/RheumaticsBiosimilarsBiotechnologyHumiraLicensingMabxienceSTADA Arzneimittel

Xencor regains rights to XmAb5871 from Amgen

29-10-2014

US drug developer Xencor revealed yesterday that it has regained all development and commercial rights…

AmgenAnti-Arthritics/RheumaticsBiotechnologyImmunologicalsLicensingResearchXencorXmAb5871

Bristol-Myers returns rights to clazakizumab to Alder BioPharma

Bristol-Myers returns rights to clazakizumab to Alder BioPharma

03-09-2014

USA-based drug developer Alder BioPharmaceuticals says it has regained the worldwide rights to clazakizumab,…

Alder BiopharmaceuticalsAnti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbclazakizumabGlobalInflammatory diseasesLicensing

3SBio licenses pegsiticase to Selecta Biosciences to develop the gout drug candidate

3SBio licenses pegsiticase to Selecta Biosciences to develop the gout drug candidate

18-06-2014

China-based biotech firm 3SBio has entered into an exclusive license with Selecta Biosciences for pegsiticase…

3SBioAnti-Arthritics/RheumaticsBiotechnologyLicensingpegsiticaseSelecta Biosciences

Celgene gains rights to Nogra product in potential $1 billion-plus deal

Celgene gains rights to Nogra product in potential $1 billion-plus deal

24-04-2014

US biotech firm Celgene has entered a global license agreement with privately-held Irish company Nogra…

Anti-Arthritics/RheumaticsBiotechnologyCelgeneGED-0301LicensingNogra Pharma

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

04-04-2014

World leading independent biotech firm Amgen revealed in a Securities and Exchange Commission filing…

AmgenAnti-Arthritics/RheumaticsBiotechnologyGlaxoSmithKlineLicensingProliaXgeva

SOBI restructures Kineret and Kepivance deals

09-09-2013

Swedish Orphan Biovitrum (STO: SOBI) said this morning that it has acquired the full rights to develop…

AmgenAnti-Arthritics/RheumaticsBiotechnologyKepivanceKineretLicensingOncologyPharmaceuticalRare diseasesSwedish Orphan Biovitrum

1 to 9 of 32 results

COMPANY SPOTLIGHT

Menarini

Back to top